Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: Preliminary Results

37Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Purpose. Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of the liver. Methods. Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n=6), IHC (n=3), and LM (n=8) are presented. Mean radiation dose was 34Gy delivered over 1-3 fractions. Results. Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6.9±4.6 cm to 5.0±2.1 cm at three months after treatment (P<.05). The mean total tumor volume reduction was 44% at six months (P<.05). 82% of all patients (14/17) achieved local control with a median follow-up of 8 months. 100% of patients with HCC (n=6) achieved local control. Patients with surgically placed fiducial markers had no complications related to marker placement. Conclusion. Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to define its role in the management of these malignancies. Copyright © 2010 K. Goyal et al.

Cite

CITATION STYLE

APA

Sanabria, J., Goyal, K., Einstein, D., Yao, M., Kunos, C., Barton, F., … Stulberg, J. (2010). Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: Preliminary Results. HPB Surgery, 2010. https://doi.org/10.1155/2010/309780

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free